MET and central nervous system cancer: Recently, however, a novel one-armed variant of the c-MET antibody 5D5 (OA5D5) was developed by Genentech (South San Francisco, CA), which acts as a pure antagonist, and can inhibit the growth of cells dependent on HGF/c-MET autocrine and paracrine signaling, and inhibit glioma growth in an orthotopic model in vivo [49, 50].